📇 Rhumatologue · COLOMBES CEDEX · (92) · Hospitalier
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Délais de RDV courts dans la région
136 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
GHU APHP NUP SITE LOUIS MOURIER
178 R DES RENOUILLIERS, 92701 COLOMBES CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Frontiers in cardiovascular medicine · 2023
IntroductionAnticoagulant is the cornerstone of the management of VTE at the cost of a non-negligible risk of bleeding. Reliable and validated clinical tools to predict thromboembolic and hemorrhagic events are crucial for individualized decision-making for the type and duration of anticoagulant treatment. We evaluate the available risk models in real life cancer patients with VTE. The objectives of the study were to describe the bleeding of cancer patients with VTE and to evaluate the performance of the different bleeding models to predict the risk of bleeding during a 6-month follow-up.Materials and MethodsVTE-diagnosed patient's demographic and clinical characteristics, treatment regimens and outcomes for up to 6 months were collected. The primary endpoint was the occurrence of a major bleeding (MB) or a clinically relevant non major bleeding (CRNMB) event, categorized according to the ISTH criteria.ResultsDuring the 6-months follow-up period, 26 out of 110 included patients (26.7%) experienced a bleeding event, with 3 recurrences of bleeding. Out of the 29 bleeding events, 19 events were CRNMB and 10 MB. One patient died because of a MB. Bleeding occurred in 27 % of the patients treated with DOACs and 22% of the patients treated with LMWH. Most of the bleedings were gastrointestinal (9 events, 31%); 26.9% of the bleedings occurred in patient with colorectal cancer and 19.6% in patients with lung cancer. In our cohort, none of the 10 RAMs used in our study were able to distinguish cancer patients with a low risk of bleeding, from all bleeding or non-bleeding patients. The Nieto et al. RAM had the best overall performance (C-statistic = 0.730, 95% CI (0.619–0.840)). However, it classified 1 out of 5 patients with major bleeding in the low risk of bleeding group. The rest of the RAMs showed a suboptimal result, with a range of C-statistic between 0.489, 95%CI (0.360–0.617)) and 0.532, 95%CI (0.406–0.658)).ConclusionsThe management of CAT patients is challenging due to a higher risk of both recurrent VTE and bleeding events, as compared with non-cancer patients with VTE. None of the existing RAMs was able to consistently identify patients with risk of anticoagulant associated bleeding events.
La Revue de medecine interne · 2025
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
La Revue de medecine interne · 2025 · English Abstract
Diakité S, Mathurin M, Lhote F, Ngo S, et al.
BMC infectious diseases · 2025 · Journal Article
Bosquet A, Affo C, Happe F, Helfer H, et al.
BMC infectious diseases · 2025 · Journal Article
Bosquet A, Affo C, Happe F, Helfer H, et al.
Frontiers in cardiovascular medicine · 2023 · Journal Article
Poénou G, Tolédano E, Helfer H, Plaisance L, et al.
Additional file 8 of COVID-19 treatment of hospital patients worldwide at the onset of the pandemic in 2020: a systematic review
Supplementary Material 8
COVID-19 treatment of hospital patients worldwide at the onset of the pandemic in 2020: a systematic review
Abstract In early 2020, no drug had proven efficacy to treat COVID-19 in-patients. This work aimed to describe COVID-19 treatment for in-patients worldwide until June, 2020. A PubMed search was performed with the terms “
Additional file 4 of COVID-19 treatment of hospital patients worldwide at the onset of the pandemic in 2020: a systematic review
Supplementary Material 4
COVID-19 treatment of hospital patients worldwide at the onset of the pandemic in 2020: a systematic review
Abstract In early 2020, no drug had proven efficacy to treat COVID-19 in-patients. This work aimed to describe COVID-19 treatment for in-patients worldwide until June, 2020. A PubMed search was performed with the terms “
Additional file 4 of COVID-19 treatment of hospital patients worldwide at the onset of the pandemic in 2020: a systematic review
Supplementary Material 4
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).
✨ Profil synthétique
IA · 04/06/2026Le Dr Edouard VERSINI est un rhumatologue hospitalier exerçant à Colombes. Ses publications sur PubMed incluent des cas cliniques, des revues et des méta-analyses, reflétant son engagement dans la recherche et la diffusion des connaissances médicales. Il contribue ainsi à l'avancement des pratiques rhumatologiques.
Expertises présumées
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.